ItAlian ReGistry Of pNeumoniA in immUnocompromised paTients (ARGONAUT)
Recruiting now
Conditions studied: Community Acquired Pneumonia (CAP)
In brief
This multicentric, prospective study aims at: evaluating the prevalence, etiology, characteristics, and 1one-year outcomes of immunocompromised patients hospitalized for Community-Acquired Pneumonia (CAP); conducting biochemical, microbiological and genetic analysis on collected samples.
Key facts
- Study ID
- NCT06755814
- Run by
- Societa Italiana di Pneumologia
- People needed
- 1298
- Starts
- 2025-08-11
- Expected to finish
- 2028-12-01
- Last updated by the study team
- 2025-11-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Hospitalized patients with a confirmed diagnosis of Community-Acquired Pneumonia (CAP) characterized by at least one of the following risk factors for immunosuppression:
- AIDS,
- Aplastic anemia;
- Asplenia;
- Hematologic malignancy (e.g., lymphoma/acute or chronic myeloid leukemia/multiple myeloma);
- Chemotherapy within the last 3 months;
- Neutropenia defined as a white blood cell count less than 500/dL on a complete blood count;
- Use of biologics (including trastuzumab and therapy for autoimmune diseases (e.g., anti-TNF α), prescribed within the last 6 months before hospital admission;
- Solid organ transplant;
- Bone marrow transplant;
- Chronic oral steroid use (>10 mg/day prednisone or equivalent ≥3 months before accessing the ED, or cumulative dose > 600 mg prednisone);
- Use of corticosteroid therapy with a dose ≥ 20 mg prednisone or equivalent ≥14 days or cumulative dose > 600 mg prednisone;
- Active malignancy;
- Malignancy within one year of pneumonia (excluding patients with localized skin cancer or early-stage malignancy);
- Lung malignancy with neutropenia/chemotherapy;
- Other solid malignancy with neutropenia/chemotherapy;
- Other immunodeficiency (including congenital/genetic immunosuppression and immunosuppressive therapy secondary to hematologic malignancy or solid malignancy);
- Primary immunodeficiency.
You may not qualify if…
- None
Where it is running
- Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milano Via Francesco Sforza 35 20122 Milan Italy — Milan, Milano, Italy (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.